Am­gen re­searchers con­firm the lack­lus­ter da­ta on the KRAS G12C drug AMG 510 re­port­ed at ES­MO — but they still have a long way to go ex­plor­ing op­tions

We learned at ES­MO that Am­gen’s star can­cer drug, the pi­o­neer­ing KRAS G12C play­er AMG 510, tend­ed to­ward the unim­pres­sive when ap­plied out­side non-small cell lung can­cer. And the re­search team has an­oth­er batch of da­ta to back that up for AS­CO.

In their Code­Break100 study, in­ves­ti­ga­tors re­port­ed on 25 pa­tients with ad­vanced tu­mors out­side of both NSCLC and col­orec­tal can­cer. Among those, they tracked 22 pa­tients for 7 weeks or longer and found 3 con­firmed par­tial re­spons­es (1 ap­pen­diceal, 1 melanoma and 1 en­dome­tri­al tu­mor). Thir­teen had sta­ble dis­ease and the rest pro­gressed.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.